CY1116887T1 - ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY - Google Patents

ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY

Info

Publication number
CY1116887T1
CY1116887T1 CY20151100984T CY151100984T CY1116887T1 CY 1116887 T1 CY1116887 T1 CY 1116887T1 CY 20151100984 T CY20151100984 T CY 20151100984T CY 151100984 T CY151100984 T CY 151100984T CY 1116887 T1 CY1116887 T1 CY 1116887T1
Authority
CY
Cyprus
Prior art keywords
human
antibodies
relates
pharmaceutical compositions
present
Prior art date
Application number
CY20151100984T
Other languages
Greek (el)
Inventor
Norihito Yazawa
Hanne Gron
Yasuhito Hamaguchi
Thomas F Tedder
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06735370.6A external-priority patent/EP1853718B1/en
Application filed by Duke University filed Critical Duke University
Publication of CY1116887T1 publication Critical patent/CY1116887T1/en

Links

Abstract

Η εφεύρεση αφορά ανοσοθεραπευτικές συνθέσεις και μεθόδους για τη θεραπευτική αγωγή ασθενειών και διαταραχών των Β κυττάρων σε ανθρώπινα υποκείμενα, όπως, αλλά χωρίς περιορισμό εκεί, κακοήθειες Β κυττάρων, μέσω της χρήσης θεραπευτικών αντισωμάτων που προσδένονται στο ανθρώπινο CD 19 αντιγόνο και που κατά προτίμηση μεσολαβούν ανθρώπινη ADCC. Η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από ανθρώπινα ή εξανθρωπισμένα αντι-CD 19 αντισώματα του IgG1 ή IgG3 ανθρώπινου ισότυπου. Η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από ανθρώπινα ή εξανθρωπισμένα αντι-CD 19 αντισώματα του IgG2 ή IgG4 ανθρώπινου ισότυπου που κατά προτίμηση μεσολαβούν ανθρώπινη ADCC. Η παρούσα εφεύρεση αφορά επίσης φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από αντι-CD19 αντισώματα του IgG1, IgG2, IgG3, ή IgG4 ισότυπου τα οποία μεσολαβούν ανθρώπινη ADCC. Σε προτιμώμενες υλοποιήσεις, η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από μονοκλωνικά ανθρώπινα, εξανθρωπισμένα, ή χιμαιρικά αντι-CD 19 αντισώματα.The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, through the use of therapeutic antibodies that bind to the human CD 19 antigen and preferably mediate ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the human IgG1 or IgG3 isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the human IgG2 or IgG4 isotype preferably mediated by human ADCC. The present invention also relates to pharmaceutical compositions comprising anti-CD19 antibodies of human ADCC mediated IgG1, IgG2, IgG3, or IgG4 isotype. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.

CY20151100984T 2005-02-15 2015-11-04 ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY CY1116887T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65358705A 2005-02-15 2005-02-15
US70206305A 2005-07-22 2005-07-22
EP06735370.6A EP1853718B1 (en) 2005-02-15 2006-02-15 Anti-cd19 antibodies and uses in oncology

Publications (1)

Publication Number Publication Date
CY1116887T1 true CY1116887T1 (en) 2017-04-05

Family

ID=58487006

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100984T CY1116887T1 (en) 2005-02-15 2015-11-04 ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY

Country Status (1)

Country Link
CY (1) CY1116887T1 (en)

Similar Documents

Publication Publication Date Title
WO2006089133A3 (en) Anti-cd19 antibodies and uses in oncology
NL301196I2 (en) inebilizumab
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
CY1119454T1 (en) ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
HRP20191609T1 (en) Protein
CY1121206T1 (en) ANTIBODIES AGAINST CD20 WITH INCREASED RELATION ASSOCIATION TO FC RECEPTOR AND OPERATOR OPERATION
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation
WO2005103081A3 (en) Human monoclonal antibodies against cd20
CY1112750T1 (en) HUMAN monoclonal anti-CD20 antibodies
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
CY1115572T1 (en) CXCR4 ANTIBODIES AND USE OF THESE FOR CANCER TREATMENT
CY1110759T1 (en) SNOWLINE DIFFERENCES AND THEIR USES
ATE557042T1 (en) ANTI-MYOSTATIN ANTIBODIES
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
UA109633C2 (en) HUMAN ANTIBODY AGAINST TISSUE FACTOR
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
EA200702634A1 (en) HUMANIZED ANTIBODIES SPECIFIC FOR NOGO-A AND THEIR PHARMACEUTICAL APPLICATIONS
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
ATE525401T1 (en) MHC CLASS I AND II PEPTIDE ANTIGENS DERIVED FROM TUMOR ANTIGEN 5T4
CY1116887T1 (en) ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY
EA202190387A1 (en) ANTIBODY TO HUMAN CD38 AND ITS USE
UA84539C2 (en) Human monoclonal antibody that specifically binds to cd40, pharmaceutical composition containing thereof and use of antibody for production of medicinal agent for treatment of cd40- negative human tumor
UA102085C2 (en) ISOLATED MONOCLONAL ANTIBODY THAT BINDS TO hGM-CSF AND COMPOSITION COMPRISING SAME